Drug Trial Radar · NCT05703009
Effects of Sacrosidase and Placebo in Subjects With Fructan Intolerance
Last checked: Nov 20, 2026Latest source record: Jun 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
25
Actual
Start
Jun 5, 2023
Primary completion
Jan 22, 2024
Study completion Jan 22, 2024
Sponsor
- Lead sponsor
- QOL Medical, LLCIndustry
- Sponsor type
- Industry
- First posted
- Jan 27, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
SSDXA-14 is a Phase 2 (feasibility/pilot) double-blind, placebo-controlled, crossover study to evaluate the efficacy and safety of sacrosidase and placebo in 25 subjects objectively diagnosed with fructan intolerance.
Conditions
- Fructan Intolerance
Interventions
Sacrosidase Oral SolutionDrug
Study drug
PlaceboDrug
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Mean (SD) Total Symptom Score (TSS) at 1 WeekTime frame: Baseline and 1 week
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Boston Specialists
Boston, Massachusetts
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.